Dupont Capital Management Corp Blueprint Medicines Corp Transaction History

Dupont Capital Management Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 27, 2022	SELL	$54.1 - $110.08 $261,789 - $532,677	-4,839 Closed	0 $0
Q4 2021 Jan 31, 2022	SELL	$94.25 - $115.99 $768,608 - $945,898	-8,155 Reduced 62.76%	4,839 $518,000
Q3 2021 Nov 03, 2021	BUY	$80.98 - $109.47 $12,794 - $17,296	158 Added 1.23%	12,994 $1.34 Million
Q2 2021 Jul 30, 2021	SELL	$82.78 - $101.0 $140,146 - $170,993	-1,693 Reduced 11.65%	12,836 $1.13 Million
Q1 2021 Apr 29, 2021	SELL	$90.71 - $108.28 $35,921 - $42,878	-396 Reduced 2.65%	14,529 $1.41 Million
Q4 2020 Jan 28, 2021	BUY	$92.08 - $124.48 $1.37 Million - $1.86 Million	14,925 New	14,925 $1.67 Million
Q2 2019 Jul 30, 2019	SELL	$73.54 - $97.8 $421,016 - $559,905	-5,725 Closed	0 $0
Q3 2018 Nov 05, 2018	SELL	$58.91 - $78.32 $386,449 - $513,779	-6,560 Reduced 53.4%	5,725 $447,000
Q1 2018 May 02, 2018	BUY	$73.28 - $102.95 $289,822 - $407,167	3,955 Added 47.48%	12,285 $1.13 Million
Q3 2017 Oct 31, 2017	BUY	$42.37 - $69.67 $352,942 - $580,351	8,330	8,330 $580,000

351

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.47B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Dupont Capital Management Corp, based on Form 13F filings with the SEC.

Stay updated on Dupont Capital Management Corp with notifications on news.